Creo has announced results for the 12-months to December 2021, reporting revenues of £25.2m up c167% supported by the annualization of acquisitions made during 2020. Sales of core Creo products were £340k (FY20A, £32k) with strong commercial progress having been made relating to procedure volumes, clinician training and sales force development. Creo continued to invest behind clinical development, headcount and infrastructure to support its future growth expectations, supported by new offices in ....
23 May 2022
Creo Medical Group Plc -- FY21 results: Strong commercial progress
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Creo Medical Group Plc -- FY21 results: Strong commercial progress
Creo Medical Group Plc (CREO:LON) | 34.2 -0.2 (-1.4%) | Mkt Cap: 123.8m
- Published:
23 May 2022 -
Author:
Chris Donnellan -
Pages:
6
Creo has announced results for the 12-months to December 2021, reporting revenues of £25.2m up c167% supported by the annualization of acquisitions made during 2020. Sales of core Creo products were £340k (FY20A, £32k) with strong commercial progress having been made relating to procedure volumes, clinician training and sales force development. Creo continued to invest behind clinical development, headcount and infrastructure to support its future growth expectations, supported by new offices in ....